Establishment of a children's Drugs and Therapeutics Committee to ensure evidence-based and cost-effective medical treatment for children
Research output: Contribution to journal › Review › Research › peer-review
Standard
Establishment of a children's Drugs and Therapeutics Committee to ensure evidence-based and cost-effective medical treatment for children. / Holst, Sara Sommer; Møller, Camilla Holten; Vermehren, Charlotte; Trolle, Stine; Hansen, Bente; Kirkedal, Ann Britt Kiholm; Christensen, Hanne Rolighed; Jacobsen, Thorkild; Mathiasen, René; Andersen, Jón Þór Traerup; Gade, Christina.
In: British Journal of Clinical Pharmacology, Vol. 90, No. 2, 2024, p. 378-387.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Establishment of a children's Drugs and Therapeutics Committee to ensure evidence-based and cost-effective medical treatment for children
AU - Holst, Sara Sommer
AU - Møller, Camilla Holten
AU - Vermehren, Charlotte
AU - Trolle, Stine
AU - Hansen, Bente
AU - Kirkedal, Ann Britt Kiholm
AU - Christensen, Hanne Rolighed
AU - Jacobsen, Thorkild
AU - Mathiasen, René
AU - Andersen, Jón Þór Traerup
AU - Gade, Christina
N1 - Funding information: This study received no funding.
PY - 2024
Y1 - 2024
N2 - The prevalence of undocumented medical treatments among children is a significant issue, as well as many EU countries lack access to newly developed children-friendly medicines. Consequently, there is a pressing need for supplementary resources that can facilitate informed decision-making regarding children's medication. We therefore aim to describe the process of establishing a children's Drug and Therapeutics Committee (cDTC), as well as the preparing and implementation of recommendations for children in the capital region of Denmark. Following the guidelines outlined by the World Health Organization, we established a cDTC, and recommendations for paediatric medication practice were constructed from assessments of medication use patterns among children in the capital region between 2019 and 2021. The recommendations were meticulously crafted based on evaluation of the current marketing authorization landscape and existing best available evidence. In 2019, the capital region established the first cDTC supported by expert councils and an editorial board. A total of 2429 purchase item numbers covering 1 222 846 defined daily doses and 592 088 purchased packages covering 10 200 000 defined daily doses were identified in the secondary and primary sectors, respectively. Three comprehensive lists covering recommendations for newborns and children were published between 2021 and 2020 totaling 331 recommended pharmaceutical products. The recommendations primarily intended for use in the secondary healthcare sector were implemented through the revision of 38 paediatric- and six neonatal product ranges throughout capital region. In conclusion, recommendation lists for children governed by a cDTC provide a rational auxiliary tool that can be immediately implemented in the clinic.
AB - The prevalence of undocumented medical treatments among children is a significant issue, as well as many EU countries lack access to newly developed children-friendly medicines. Consequently, there is a pressing need for supplementary resources that can facilitate informed decision-making regarding children's medication. We therefore aim to describe the process of establishing a children's Drug and Therapeutics Committee (cDTC), as well as the preparing and implementation of recommendations for children in the capital region of Denmark. Following the guidelines outlined by the World Health Organization, we established a cDTC, and recommendations for paediatric medication practice were constructed from assessments of medication use patterns among children in the capital region between 2019 and 2021. The recommendations were meticulously crafted based on evaluation of the current marketing authorization landscape and existing best available evidence. In 2019, the capital region established the first cDTC supported by expert councils and an editorial board. A total of 2429 purchase item numbers covering 1 222 846 defined daily doses and 592 088 purchased packages covering 10 200 000 defined daily doses were identified in the secondary and primary sectors, respectively. Three comprehensive lists covering recommendations for newborns and children were published between 2021 and 2020 totaling 331 recommended pharmaceutical products. The recommendations primarily intended for use in the secondary healthcare sector were implemented through the revision of 38 paediatric- and six neonatal product ranges throughout capital region. In conclusion, recommendation lists for children governed by a cDTC provide a rational auxiliary tool that can be immediately implemented in the clinic.
KW - clinical pharmacology
KW - Drugs and Therapeutics Committee
KW - formulary list
KW - neonatal
KW - paediatrics
U2 - 10.1111/bcp.15944
DO - 10.1111/bcp.15944
M3 - Review
C2 - 37879905
AN - SCOPUS:85178882062
VL - 90
SP - 378
EP - 387
JO - British Journal of Clinical Pharmacology, Supplement
JF - British Journal of Clinical Pharmacology, Supplement
SN - 0264-3774
IS - 2
ER -
ID: 380201755